Thompson Investment Management Has Decreased Ingersoll (IR) Stake By $348,075; Shorts at TG Therapeutics (TGTX) Lowered By 6.31%

October 13, 2017 - By Clifton Ray

Thompson Investment Management Inc decreased Ingersoll (IR) stake by 23.08% reported in 2017Q2 SEC filing. Thompson Investment Management Inc sold 3,825 shares as Ingersoll (IR)’s stock rose 10.19%. The Thompson Investment Management Inc holds 12,750 shares with $1.17M value, down from 16,575 last quarter. Ingersoll now has $23.36 billion valuation. The stock rose 0.79% or $0.72 reaching $92.1. About 13,460 shares traded. Ingersoll-Rand PLC (NYSE:IR) has risen 39.42% since October 13, 2016 and is uptrending. It has outperformed by 22.72% the S&P500.

TG Therapeutics Incorporated (NASDAQ:TGTX) had a decrease of 6.31% in short interest. TGTX’s SI was 17.25M shares in October as released by FINRA. Its down 6.31% from 18.41 million shares previously. With 1.00M avg volume, 17 days are for TG Therapeutics Incorporated (NASDAQ:TGTX)’s short sellers to cover TGTX’s short positions. The SI to TG Therapeutics Incorporated’s float is 51.39%. About shares traded. TG Therapeutics Inc (NASDAQ:TGTX) has risen 60.54% since October 13, 2016 and is uptrending. It has outperformed by 43.84% the S&P500.

Thompson Investment Management Inc increased Hd Supply Hldgs Inc Com (NASDAQ:HDS) stake by 17,256 shares to 129,665 valued at $3.97M in 2017Q2. It also upped Freeport (NYSE:FCX) stake by 63,451 shares and now owns 462,053 shares. Cpi Card Group Inc Com was raised too.

Among 21 analysts covering Ingersoll-Rand Plc (NYSE:IR), 12 have Buy rating, 0 Sell and 9 Hold. Therefore 57% are positive. Ingersoll-Rand Plc had 53 analyst reports since July 30, 2015 according to SRatingsIntel. The stock has “Neutral” rating by Susquehanna on Thursday, April 14. The stock of Ingersoll-Rand PLC (NYSE:IR) earned “Buy” rating by BMO Capital Markets on Friday, April 21. RBC Capital Markets maintained the stock with “Hold” rating in Monday, July 10 report. The firm earned “Buy” rating on Monday, September 11 by Jefferies. The rating was maintained by Argus Research with “Buy” on Monday, August 3. RBC Capital Markets maintained Ingersoll-Rand PLC (NYSE:IR) rating on Thursday, September 28. RBC Capital Markets has “Hold” rating and $93.0 target. The firm earned “Buy” rating on Tuesday, April 19 by Citigroup. The stock of Ingersoll-Rand PLC (NYSE:IR) earned “Buy” rating by Jefferies on Monday, April 3. On Wednesday, October 28 the stock rating was maintained by Stifel Nicolaus with “Buy”. The rating was maintained by RBC Capital Markets with “Hold” on Monday, June 5.

Investors sentiment decreased to 0.88 in Q2 2017. Its down 0.14, from 1.02 in 2017Q1. It is negative, as 45 investors sold IR shares while 217 reduced holdings. 71 funds opened positions while 159 raised stakes. 201.02 million shares or 1.95% less from 205.01 million shares in 2017Q1 were reported. Northeast Financial Consultants Inc owns 0.25% invested in Ingersoll-Rand PLC (NYSE:IR) for 6,877 shares. Great West Life Assurance Com Can, a Manitoba – Canada-based fund reported 202,317 shares. Eagle Glob Advisors Limited Co, a Texas-based fund reported 113,289 shares. Westfield Management Lp has invested 0.86% of its portfolio in Ingersoll-Rand PLC (NYSE:IR). Meiji Yasuda Asset Management accumulated 0.07% or 7,129 shares. Srb Corporation holds 0.03% of its portfolio in Ingersoll-Rand PLC (NYSE:IR) for 2,033 shares. First Bancorporation reported 11,640 shares. 140 are owned by Jnba Finance Advisors. First Interstate Savings Bank accumulated 0.01% or 763 shares. Balyasny Asset Limited Com invested in 0% or 3,233 shares. Bb&T has 0.06% invested in Ingersoll-Rand PLC (NYSE:IR) for 32,130 shares. Anchor Bolt Cap Lp invested 2.36% in Ingersoll-Rand PLC (NYSE:IR). Rothschild Asset Mgmt, a New York-based fund reported 220,092 shares. Symphony Asset Lc holds 15,865 shares. Moreover, Fruth Investment Mngmt has 1.1% invested in Ingersoll-Rand PLC (NYSE:IR).

Analysts await Ingersoll-Rand PLC (NYSE:IR) to report earnings on October, 25. They expect $1.44 earnings per share, up 2.13% or $0.03 from last year’s $1.41 per share. IR’s profit will be $365.24 million for 15.99 P/E if the $1.44 EPS becomes a reality. After $1.49 actual earnings per share reported by Ingersoll-Rand PLC for the previous quarter, Wall Street now forecasts -3.36% negative EPS growth.

Investors sentiment increased to 2.28 in 2017 Q2. Its up 0.25, from 2.03 in 2017Q1. It is positive, as 6 investors sold TG Therapeutics Inc shares while 19 reduced holdings. 18 funds opened positions while 39 raised stakes. 33.91 million shares or 12.20% more from 30.22 million shares in 2017Q1 were reported. Barclays Public Ltd Com has 54,077 shares. Gru Inc One Trading L P reported 0.01% of its portfolio in TG Therapeutics Inc (NASDAQ:TGTX). The Texas-based Hwg Holdings Lp has invested 0.01% in TG Therapeutics Inc (NASDAQ:TGTX). American International Gp invested 0% in TG Therapeutics Inc (NASDAQ:TGTX). Zurcher Kantonalbank (Zurich Cantonalbank) invested in 0% or 2,255 shares. Artal Gru reported 500,000 shares. Tiaa Cref Limited Liability Company reported 165,741 shares or 0% of all its holdings. Pacad Limited holds 800 shares. 59,940 were reported by Alliancebernstein Lp. Panagora Asset Mngmt reported 83,229 shares stake. State Board Of Administration Of Florida Retirement, Florida-based fund reported 14,771 shares. Legal General Gp Public Ltd Co has 11,264 shares. Kennedy Cap Mngmt owns 0.11% invested in TG Therapeutics Inc (NASDAQ:TGTX) for 565,178 shares. Raymond James Advisors stated it has 0% in TG Therapeutics Inc (NASDAQ:TGTX). California State Teachers Retirement Sys invested in 85,935 shares or 0% of the stock.

Since June 16, 2017, it had 0 insider buys, and 1 insider sale for $665,133 activity. Power Sean A also sold $665,133 worth of TG Therapeutics Inc (NASDAQ:TGTX) shares.

TG Therapeutics, Inc. is a biopharmaceutical firm focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases. The company has market cap of $770.96 million. As of December 31, 2016, the Company was developing two therapies targeting hematological malignancies. It currently has negative earnings. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the cluster of differentiation (CD20) antigen found on mature B-lymphocytes.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

>